# WD-930

Source: https://onco.cc/drugs/wd-930/  
OnCo record `wd-930` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

WD-930 is an experimental small molecule from Zhejiang Wenda Pharma, in preclinical development for advanced cancer; its current status is not stated.

## Summary

WD-930 is a small molecule from Zhejiang Wenda Pharma. Described only as a brain-penetrant, highly selective inhibitor with a 'trapping' function, being explored for cancer. The target is not named. Its furthest stage is preclinical development, for advanced cancer (unspecified). No clinical trial naming it is registered on ClinicalTrials.gov. No stage given on the pipeline page and no registered trial found; listed for 'Advanced cancer'. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: WD-930
- Modality: Small molecule
- Mechanism: Described only as a brain-penetrant, highly selective inhibitor with a 'trapping' function, being explored for cancer. The target is not named.

## Sources

- Zhejiang Wenda Pharma: wendapharma.com: https://www.wendapharma.com/pipeline.php
- Zhejiang Wenda Pharma: wendapharma.com: https://www.wendapharma.com/pipeline.php

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Zhejiang Wenda Pharma](https://onco.cc/companies/zhejiang-wenda-pharma/)

---
JSON: https://onco.cc/api/v1/entities/wd-930.json